Home > Resources > Whitepapers > Nanotechnology

Nanotechnology

June 6, 2018

Nanotechnology is now a mature subject in terms of the basic science, and while there were many claims for what it could achieve 20 years ago when the funding in the area was beginning to ramp up, there is now much more realism in most areas of application. The application to medicine and healthcare is certainly now much more well defined. There have also been some harsh lessons learned in the past 15 years or so as to the limitations being set by regulation, professional and public acceptance and by the funding agencies, both public and private.

Spotlight

IBC Generium

IBC Generium is a scientific research company with a mission to develop safe and effective biotechnology-based medical products and cell-based technologies to the stage of industrial application.

OTHER WHITEPAPERS

Three Trends to Watch in Life Sciences

whitePaper | June 10, 2022

Healthcare is changing rapidly. Companies who provide products and services to hospitals and physicians will need to adjust their operations to change.

How Can Biotechnology and Pharmaceutical Industries Better Weather This New Economy?

whitePaper | October 10, 2022

Biotechnology and pharmaceutical industries continue to experience increased pressure on financial performance due to several factors.

HIGH THROUGHPUT AAV VIRAL TITERING USING NANOPLATE-BASED DIGITAL PCR

whitePaper | December 22, 2022

Determining the physical titer of viral vectors has typically been accomplished using digital droplet PCR (ddPCR). Droplet-based methods, however, are challenged by matrix effects and long analysis times (up to 7 hours).

Growing a circular economy with fungalbiotechnology

whitePaper | October 22, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans

The US Bioeconomy

whitePaper | April 14, 2022

In the nearly 50 years since the first genetic engineering experiments, the United States has become the world’s biotechnology powerhouse,

Covid-19 Vaccine Distribution System

whitePaper | April 14, 2021

Delivering Covid-19 vaccines to 7.8 billion people is a daunting challenge that will stretch supply chains past their limits. Even if all the needed doses were ready today, vaccine manufacturers still must find solutions to deliver multiple doses of those vaccines to most people on the planet. To read more, please download this free white paper.